[General Information]
[Abstracts]
[How to Contact Us]
 

Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS)* in the advanced cancer patients

[Investigative New Drugs 13:89-97, 1995]

Vladimir A. Filov, Michail L. Gershanovich, Lidia A. Danova and Boris A. Ivin
Prof. N.N. Petrov Research Institute of Oncology, Pesochny-2, St. Petersburg, 189646, Russia

Key words: Sehydrin, Hydrazine Sulfate, advanced cancer, chemotherapy

Summary

The results of Sehydrin (Hydrazine Sulfate, HS) treatment of 740 patients with the advanced, recurrent or metastatic solid tumours of various localizations or malignant lymphomas, for whom all the methods of specific treatment (surgery, radiation, chemotherapy) had been exhausted are presented in this work. The objective response, symptomatic therapeutic effects and toxicity were estimated. Clinically significant objective responses were registered in patients with the soft tissue sarcomas, including neuroblastomas, and paradoxically – in such semimalignant tumours as desmoids. Although the objective response in patients with the lung cancer (90% - non-small cell) was only 4%, stabilization of long duration was registered in 22% of cases connected with the impressive relief of heavy common symptoms in 38.5% of the treated patients. Such a subjective response was established in 46.6% of all the 740 cases. The drug given per os was well tolerated by patients in primary and subsequent courses and did not induce myelosuppression or other significant side effects. On the basis of observations available, Sehydrin may be assess as an alternative drug for the treatment and symptomatic therapy of patients with some advanced solid tumours and malignant lymphomas at a disease stage when the other methods of treatment can not be used. A possible mechanism of antitumour and symptomatic action is being discussed.


This page is designed and hosted by Next Generation Computer Systems, and is the property of the Syracuse Cancer Research Institute. 1996, Syracuse Cancer Research Institute. All rights reserved.
Last modified on 22 September 1998 by
webteam@ngen.com.